Form 4: Vericel Corp Chief Medical Officer Exercises Options and Sells Shares

Vericel Corp's Chief Medical Officer, Jonathan Hopper, exercised stock options and sold 10,000 shares of common stock on December 2, 2024, according to a recent SEC filing.

Summary

• Jonathan Hopper, Chief Medical Officer of Vericel Corp, executed a transaction involving the company's stock on December 2, 2024.
• He exercised options to acquire 10,000 shares of common stock at a price of $16.66 per share.
• Concurrently, he sold 10,000 shares of common stock at a price of $58.72 per share.
• These transactions were part of a pre-arranged trading plan under Rule 10b5-1, adopted on May 28, 2024.
• Following these transactions, Mr. Hopper directly owns 58,371 shares of Vericel Corp common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.
• The price difference between the exercise price and the sale price is consistent with the potential profit from stock options.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan.
• The sale of shares by an executive may be perceived as a negative signal by some investors, but the pre-arranged nature mitigates this concern.

Key Dates

Keywords

Vericel Corp, stock options, insider trading, SEC Form 4, Rule 10b5-1, Jonathan Hopper, stock sale, executive compensation